Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Eliglustat. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UGCG known ✓ | Q16739 | 14/20 | 1.00 |
| ▸ | HTR1A | P08908 | 1/20 | 1.00 |
| ▸ | PTGS1 | P23219 | 1/20 | 1.00 |
| ▸ | OPRM1 | P35372 | 1/20 | 1.00 |
| ▸ | MEN1 | O00255 | 2/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.62 |
| ▸ | TP53 | P04637 | 2/20 | 0.62 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.62 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.62 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.62 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.62 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.62 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.62 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.62 |
| ▸ | MAPT | P10636 | 1/20 | 0.62 |
| ▸ | MTOR | P42345 | 1/20 | 0.62 |
| ▸ | GMNN | O75496 | 1/20 | 0.61 |
| ▸ | LMNA | P02545 | 1/20 | 0.61 |
| ▸ | BLM | P54132 | 1/20 | 0.61 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2169484 | 1.00 | UGCG (1.00) | UGCGHTR1APTGS1OPRM1MEN1 | |
| Eliglustat SCHEMBL4057024 | 1.00 | UGCG (1.00) | UGCGHTR1APTGS1OPRM1MEN1 | |
| SCHEMBL4067738 | 1.00 | UGCG (1.00) | UGCGHTR1APTGS1OPRM1MEN1 | |
| SCHEMBL419334 | 1.00 | UGCG (1.00) | UGCGHTR1APTGS1OPRM1MEN1 | |
| Eliglustat SCHEMBL21648647 | 1.00 | UGCG (1.00) | UGCGHTR1APTGS1OPRM1MEN1 | |
| Eliglustat SCHEMBL21252721 | 1.00 | UGCG (1.00) | UGCGHTR1APTGS1OPRM1MEN1 | |
| SCHEMBL1085008 | 1.00 | UGCG (1.00) | UGCGHTR1APTGS1OPRM1MEN1 | |
| SCHEMBL12091633 | 1.00 | UGCG (1.00) | UGCGHTR1APTGS1OPRM1MEN1 | |
| Eliglustat SCHEMBL4058275 | 1.00 | UGCG (1.00) | UGCGHTR1APTGS1OPRM1MEN1 | |
| SCHEMBL761669 | 1.00 | UGCG (1.00) | UGCGHTR1APTGS1OPRM1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 75 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3080602-B1 | TREATING NEURODEGENERATIVE DISEASE | BRIGHAM & WOMENS HOSPITAL INC (US) | 2018-11-28 | — | — | EP | claimed |
| EP-1811991-B1 | Treatment of type 2 diabetes using inhibitors of glycosphingolipid synthesis | GENZYME CORP (US) | 2018-11-07 | — | — | EP | claimed |
| US-9927437-B2 | Treating neurodegenerative disease | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2018-03-27 | — | — | US | claimed |
| US-20170281593-A1 | Methods of Treating Fatty Liver Disease | GENZYME CORPORATION | 2017-10-05 | — | — | US | claimed |
| US-9532976-B2 | Method of lowering blood glucose | GENZYME CORPORATION (US) | 2017-01-03 | — | — | US | claimed |
| US-20160313324-A1 | TREATING NEURODEGENERATIVE DISEASE | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2016-10-27 | — | — | US | claimed |
| EP-3080602-A2 | TREATING NEURODEGENERATIVE DISEASE | The Brigham and Women's Hospital, Inc. (US) | 2016-10-19 | — | — | EP | claimed |
| EP-2923699-A1 | METHODS OF TREATING FATTY LIVER DISEASE | Genzyme Corporation (US) | 2015-09-30 | — | — | EP | claimed |
| EP-2032134-B1 | METHODS OF TREATING FATTY LIVER DISEASE COMPRISING INHIBITING GLUCOSPHINGOLIPID SYNTHESIS | GENZYME CORP (US) | 2015-06-24 | — | — | EP | claimed |
| WO-2015089443-A2 | TREATING NEURODEGENERATIVE DISEASE | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2015-06-18 | — | — | WO | claimed |
| US-8716327-B2 | Methods of treating fatty liver disease | GENZYME CORPORATION (US) | 2014-05-06 | — | — | US | claimed |
| US-20120022126-A1 | Method Of Treating Diabetes Mellitus | GENZYME CORPORATION (US) | 2012-01-26 | — | — | US | claimed |
| US-8003617-B2 | e.g. 1-(3',4'-ethylenedioxy)phenyl-2-nonanoylamino-3-pyrrolidino-1-propanol; glucosylceramide synthase inhibitor; inhibits glycosphingolipid synthesis; antidiabetic, hypoglycemic agent; non-insulin dependent diabetes, obesity, Gaucher's disease | GENZYME CORPORATION (US) | 2011-08-23 | — | — | US | claimed |
| US-20090105125-A1 | Methods of Treating Fatty Liver Disease | GENZYME CORPORATION | 2009-04-23 | — | — | US | claimed |
| EP-2032134-A2 | METHODS OF TREATING FATTY LIVER DISEASE COMPRISING INHIBITING GLUCOSPHINGOLIPID SYNTHESIS | Genzyme Corporation (US) | 2009-03-11 | — | — | EP | claimed |
| US-20080161379-A1 | Methods of Treating Diabetes Mellitus | GENZYME CORPORATION | 2008-07-03 | — | — | US | claimed |
| WO-2007134086-A2 | METHODS OF TREATING FATTY LIVER DISEASE COMPRISING INHIBITING GLUCOSPHINGOLIPID SYNTHESIS | GENZYME CORPORATION (US) | 2007-11-22 | — | — | WO | claimed |
| EP-1811991-A2 | METHODS OF TREATING DIABETES MELLITUS | Genzyme Corporation (US) | 2007-08-01 | — | — | EP | claimed |
| WO-2006053043-A2 | METHODS OF TREATING DIABETES MELLITUS | GENZYME CORPORATION (US) | 2006-05-18 | — | — | WO | claimed |
| WO-2024127407-A1 | VIROPORINS BLOCKERS/INHIBITORS AS ANTI-INFLUENZA AGENTS | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2024-06-20 | — | — | WO | disclosed |
| CN-111217791-B | Ibrutin intermediate and preparation method thereof | 广东东阳光药业股份有限公司 | 2024-02-02 | — | — | CN | disclosed |
| WO-2024018382-A1 | BIOMARKERS OF LYSOSOMAL STORAGE DISEASE | GENZYME CORPORATION (US) | 2024-01-25 | — | — | WO | disclosed |
| WO-2023228091-A1 | METHODS FOR IDENTIFYING AND TREATING DISEASES | GENZYME CORPORATION (US) | 2023-11-30 | — | — | WO | disclosed |
| US-11760741-B2 | Pro-drugs of eliglustat | KASHIV BIOSCIENCES, LLC (US) | 2023-09-19 | — | — | US | disclosed |
| US-11760741-B2 | Pro-drugs of eliglustat | KASHIV BIOSCIENCES, LLC (US) | 2023-09-19 | — | — | US | disclosed |
| WO-2023118113-A1 | COMPOUNDS TIRAPAZAMINE AND QUAZINONE FOR USE IN THE TREATMENT OF GM2 GANGLIOSIDOSES | SOM INNOVATION BIOTECH, S.A. (ES) | 2023-06-29 | — | — | WO | disclosed |
| EP-4201403-A1 | COMPOUNDS TIRAPAZAMINE AND QUAZINONE FOR USE IN THE TREATMENT OF GM2 GANGLIOSIDOSES | Som Innovation Biotech, S.L. (ES) | 2023-06-28 | — | — | EP | disclosed |
| US-20210300887-A1 | PRO-DRUGS OF ELIGLUSTAT | AMNEAL PHARMACEUTICALS LLC | 2021-09-30 | — | — | US | disclosed |
| EP-3723809-A1 | METHODS FOR TREATING GAUCHER DISEASE | Genzyme Corporation (US) | 2020-10-21 | — | — | EP | disclosed |
| US-20200306225-A1 | STABLE N-((1R,2R)-1-(2,3-DIHYDROBENZO[B][1,4]DIOXIN-6-YL)-1-HYDROXY-3-(PYRROLIDIN-1-YL)PROPAN-2-YL) OCTANAMIDE (2R,3R)-2,3-DIHYDROXYSUCCINATE PREMIX AND PROCESS FOR PREPARATION THEREOF | MSN LABORATORIES PRIVATE LTD R&D CENTER (IN) | 2020-10-01 | — | — | US | disclosed |
| EP-2968268-B1 | INHIBITORS OF THE ENZYME UDP-GLUCOSE: N-ACYL-SPHINGOSINE GLUCOSYLTRANSFERASE | CONCERT PHARMACEUTICALS INC (US) | 2020-07-29 | — | — | EP | disclosed |
| CN-111217791-A | Ibrustat intermediate and preparation method thereof | 广东东阳光药业有限公司 | 2020-06-02 | — | — | CN | disclosed |
| WO-2020020365-A1 | METHOD FOR PREPARING OPTICALLY ACTIVE ELIGLUSTAT | 中国医学科学院药物研究所 | 2020-01-30 | — | — | WO | disclosed |
| US-10385042-B2 | Inhibitors of the enzyme UDP-glucose: N-acyl-sphingosine glucosyltransferase | CONCERT PHARMACEUTICALS, INC. (US) | 2019-08-20 | — | — | US | disclosed |
| WO-2019118707-A1 | METHODS FOR TREATING GAUCHER DISEASE | GENZYME CORPORATION (US) | 2019-06-20 | — | — | WO | disclosed |
| EP-3442514-A1 | INHIBITORS OF GLUCOSYLCERAMIDE DEGRADATION IN THE TREATMENT OF DISEASES OF THE MOTOR UNITS | Spedding Research Solutions (FR) | 2019-02-20 | — | — | EP | disclosed |
| EP-2550965-B1 | Ceramide derivatives for treating polycystic kidney disease | GENZYME CORP (US) | 2019-01-16 | — | — | EP | disclosed |
| EP-3080602-B1 | TREATING NEURODEGENERATIVE DISEASE | BRIGHAM & WOMENS HOSPITAL INC (US) | 2018-11-28 | — | — | EP | disclosed |
| EP-1811991-B1 | Treatment of type 2 diabetes using inhibitors of glycosphingolipid synthesis | GENZYME CORP (US) | 2018-11-07 | — | — | EP | disclosed |
| EP-2923699-B1 | METHODS OF TREATING FATTY LIVER DISEASE COMPRISING INHIBITING GLUCOSPHINGOLIPID SYNTHESIS | GENZYME CORP (US) | 2018-06-20 | — | — | EP | disclosed |
| US-20180086743-A1 | INHIBITORS OF THE ENZYME UDP-GLUCOSE: N-ACYL-SPHINGOSINE GLUCOSYLTRANSFERASE | CONCERT PHARMACEUTICALS, INC. (US) | 2018-03-29 | — | — | US | disclosed |
| US-9927437-B2 | Treating neurodegenerative disease | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2018-03-27 | — | — | US | disclosed |
| WO-2017178499-A1 | INHIBITORS OF GLUCOSYLCERAMIDE DEGRADATION IN THE TREATMENT OF DISEASES OF THE MOTOR UNITS | SPEDDING RESEARCH SOLUTIONS (FR) | 2017-10-19 | — | — | WO | disclosed |
| US-9783528-B2 | Inhibitors of the enzyme UDP-glucose: N-acyl-sphingosine glucosyltransferase | CONCERT PHARMACEUTICALS, INC. (US) | 2017-10-10 | — | — | US | disclosed |
| US-20170281593-A1 | Methods of Treating Fatty Liver Disease | GENZYME CORPORATION | 2017-10-05 | — | — | US | disclosed |
| US-20170281593-A1 | Methods of Treating Fatty Liver Disease | GENZYME CORPORATION | 2017-10-05 | — | — | US | disclosed |
| WO-2017068496-A1 | IMPROVED PROCESS FOR THE PREPARATION OF ELIGLUSTAT AND ITS SALTS | DR. REDDY' S LABORATORIES LIMITED (IN) | 2017-04-27 | — | — | WO | disclosed |
| US-9556155-B2 | Methods of treating fatty liver disease | GENZYME CORPORATION (US) | 2017-01-31 | — | — | US | disclosed |
| US-9556155-B2 | Methods of treating fatty liver disease | GENZYME CORPORATION (US) | 2017-01-31 | — | — | US | disclosed |
| US-20160313324-A1 | TREATING NEURODEGENERATIVE DISEASE | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2016-10-27 | — | — | US | disclosed |
| EP-3080602-A2 | TREATING NEURODEGENERATIVE DISEASE | The Brigham and Women's Hospital, Inc. (US) | 2016-10-19 | — | — | EP | disclosed |
| US-20160068519-A1 | INHIBITORS OF THE ENZYME UDP-GLUCOSE: N-ACYL-SPHINGOSINE GLUCOSYLTRANSFERASE | CONCERT PHARMACEUTICALS, INC. (US) | 2016-03-10 | — | — | US | disclosed |
| EP-2968268-A1 | INHIBITORS OF THE ENZYME UDP-GLUCOSE: N-ACYL-SPHINGOSINE GLUCOSYLTRANSFERASE | Concert Pharmaceuticals Inc. (US) | 2016-01-20 | — | — | EP | disclosed |
| EP-2923699-A1 | METHODS OF TREATING FATTY LIVER DISEASE | Genzyme Corporation (US) | 2015-09-30 | — | — | EP | disclosed |
| EP-2032134-B1 | METHODS OF TREATING FATTY LIVER DISEASE COMPRISING INHIBITING GLUCOSPHINGOLIPID SYNTHESIS | GENZYME CORP (US) | 2015-06-24 | — | — | EP | disclosed |
| WO-2015089443-A2 | TREATING NEURODEGENERATIVE DISEASE | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2015-06-18 | — | — | WO | disclosed |
| US-20150051261-A1 | Methods of Treating Fatty Liver Disease | GENZYME CORPORATION (US) | 2015-02-19 | — | — | US | disclosed |
| US-20150051261-A1 | Methods of Treating Fatty Liver Disease | GENZYME CORPORATION (US) | 2015-02-19 | — | — | US | disclosed |
| US-8912177-B2 | Method of treating polycystic kidney diseases with ceramide derivatives | GENZYME CORPORATION (US) | 2014-12-16 | — | — | US | disclosed |
| WO-2014150043-A1 | INHIBITORS OF THE ENZYME UDP-GLUCOSE: N-ACYL-SPHINGOSINE GLUCOSYLTRANSFERASE | CONCERT PHARMACEUTICALS INC. (US) | 2014-09-25 | — | — | WO | disclosed |
| US-8716327-B2 | Methods of treating fatty liver disease | GENZYME CORPORATION (US) | 2014-05-06 | — | — | US | disclosed |
| US-8716327-B2 | Methods of treating fatty liver disease | GENZYME CORPORATION (US) | 2014-05-06 | — | — | US | disclosed |
| US-20120022126-A1 | Method Of Treating Diabetes Mellitus | GENZYME CORPORATION (US) | 2012-01-26 | — | — | US | disclosed |
| US-20120022126-A1 | Method Of Treating Diabetes Mellitus | GENZYME CORPORATION (US) | 2012-01-26 | — | — | US | disclosed |
| US-8003617-B2 | e.g. 1-(3',4'-ethylenedioxy)phenyl-2-nonanoylamino-3-pyrrolidino-1-propanol; glucosylceramide synthase inhibitor; inhibits glycosphingolipid synthesis; antidiabetic, hypoglycemic agent; non-insulin dependent diabetes, obesity, Gaucher's disease | GENZYME CORPORATION (US) | 2011-08-23 | — | — | US | disclosed |
| US-8003617-B2 | e.g. 1-(3',4'-ethylenedioxy)phenyl-2-nonanoylamino-3-pyrrolidino-1-propanol; glucosylceramide synthase inhibitor; inhibits glycosphingolipid synthesis; antidiabetic, hypoglycemic agent; non-insulin dependent diabetes, obesity, Gaucher's disease | GENZYME CORPORATION (US) | 2011-08-23 | — | — | US | disclosed |
| US-20100298317-A1 | METHOD OF TREATING POLYCYSTIC KIDNEY DISEASES WITH CERAMIDE DERIVATIVES | GENZYME CORPORATION | 2010-11-25 | — | — | US | disclosed |
| US-20090105125-A1 | Methods of Treating Fatty Liver Disease | GENZYME CORPORATION | 2009-04-23 | — | — | US | disclosed |
| US-20090105125-A1 | Methods of Treating Fatty Liver Disease | GENZYME CORPORATION | 2009-04-23 | — | — | US | disclosed |
| EP-2032134-A2 | METHODS OF TREATING FATTY LIVER DISEASE COMPRISING INHIBITING GLUCOSPHINGOLIPID SYNTHESIS | Genzyme Corporation (US) | 2009-03-11 | — | — | EP | disclosed |
| US-20080161379-A1 | Methods of Treating Diabetes Mellitus | GENZYME CORPORATION | 2008-07-03 | — | — | US | disclosed |
| US-20080161379-A1 | Methods of Treating Diabetes Mellitus | GENZYME CORPORATION | 2008-07-03 | — | — | US | disclosed |
| WO-2007134086-A2 | METHODS OF TREATING FATTY LIVER DISEASE COMPRISING INHIBITING GLUCOSPHINGOLIPID SYNTHESIS | GENZYME CORPORATION (US) | 2007-11-22 | — | — | WO | disclosed |
| EP-1811991-A2 | METHODS OF TREATING DIABETES MELLITUS | Genzyme Corporation (US) | 2007-08-01 | — | — | EP | disclosed |
| WO-2006053043-A2 | METHODS OF TREATING DIABETES MELLITUS | GENZYME CORPORATION (US) | 2006-05-18 | — | — | WO | disclosed |
| WO-2006053043-A2 | METHODS OF TREATING DIABETES MELLITUS | GENZYME CORPORATION (US) | 2006-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10385042-B2 | Inhibitors of the enzyme UDP-glucose: N-acyl-sphingosine glucosyltransferase | UGCG, UGGT1, OGT | UGCG 1/4885HTR1A 3831/4885PTGS1 2129/4885 |
| US-20150051261-A1 | Methods of Treating Fatty Liver Disease | LIPC, GYS2, PNLIP | UGCG 7/4885HTR1A 3913/4885PTGS1 1157/4885 |
| US-20170281593-A1 | Methods of Treating Fatty Liver Disease | LIPC, GYS2, PNLIP | UGCG 7/4885HTR1A 3913/4885PTGS1 1157/4885 |
| US-20120022126-A1 | Method Of Treating Diabetes Mellitus | ASAH2, ASAH1, GBA1 | UGCG 4/4885HTR1A 3224/4885PTGS1 607/4885 |
| US-20200306225-A1 | STABLE N-((1R,2R)-1-(2,3-DIHYDROBENZO[B][1,4]DIOXIN-6-YL)-1-HYDROXY-3-(PYRROLIDIN-1-YL)PROPAN-2-YL) OCTANAMIDE (2R,3R)-2,3-DIHYDROXYSUCCINATE PREMIX AND PROCESS FOR PREPARATION THEREOF | HPD, CYP1B1, CYP4X1 | UGCG 4364/4885HTR1A 30/4885PTGS1 654/4885 |
| US-11760741-B2 | Pro-drugs of eliglustat | GCG, GLP1R, PROKR1 | UGCG 580/4885HTR1A 1244/4885PTGS1 517/4885 |
| US-20090105125-A1 | Methods of Treating Fatty Liver Disease | LIPC, GYS2, PNLIP | UGCG 7/4885HTR1A 3913/4885PTGS1 1157/4885 |
| US-20210300887-A1 | PRO-DRUGS OF ELIGLUSTAT | GCG, GLP1R, PROKR1 | UGCG 580/4885HTR1A 1244/4885PTGS1 517/4885 |
| US-20160068519-A1 | INHIBITORS OF THE ENZYME UDP-GLUCOSE: N-ACYL-SPHINGOSINE GLUCOSYLTRANSFERASE | UGCG, UGGT1, OGT | UGCG 1/4885HTR1A 3831/4885PTGS1 2129/4885 |
| US-20180086743-A1 | INHIBITORS OF THE ENZYME UDP-GLUCOSE: N-ACYL-SPHINGOSINE GLUCOSYLTRANSFERASE | UGCG, UGGT1, OGT | UGCG 1/4885HTR1A 3831/4885PTGS1 2129/4885 |
| US-20080161379-A1 | Methods of Treating Diabetes Mellitus | ASAH2, PNLIP, ASAH1 | UGCG 4/4885HTR1A 3041/4885PTGS1 524/4885 |
| US-20100298317-A1 | METHOD OF TREATING POLYCYSTIC KIDNEY DISEASES WITH CERAMIDE DERIVATIVES | SGMS1, SGMS2, CERS2 | UGCG 27/4885HTR1A 3534/4885PTGS1 1154/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.